{"title":"Teneligliptin – The Newest DPP4 Inhibitor","authors":"M. Kiran, H. Chandalia","doi":"10.22376/IJPBS.2017.8.2.P163-178","DOIUrl":null,"url":null,"abstract":"Teneligliptin is the newest DPP4 inhibitor approved by the regulatory authority for the treatment of Diabetes mellitus. Teneligliptin scores over other 'gliptins' in being more economical and with better efficacy to control blood glucose and HbA1C levels. Teneligliptin additionally offers other pharmacological advantages like longer half-life, lesser IC50 value, tight and extensive binding to the DPP4 enzyme. Teneligliptin has been studies extensively for its safety and efficacy in various clinical trials conducted internationally. This review article comprehensively documents the available clinical and pharmacological data for Teneligliptin in the treatment of Diabetes mellitus.","PeriodicalId":22419,"journal":{"name":"The Indian practitioner","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Indian practitioner","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22376/IJPBS.2017.8.2.P163-178","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Teneligliptin is the newest DPP4 inhibitor approved by the regulatory authority for the treatment of Diabetes mellitus. Teneligliptin scores over other 'gliptins' in being more economical and with better efficacy to control blood glucose and HbA1C levels. Teneligliptin additionally offers other pharmacological advantages like longer half-life, lesser IC50 value, tight and extensive binding to the DPP4 enzyme. Teneligliptin has been studies extensively for its safety and efficacy in various clinical trials conducted internationally. This review article comprehensively documents the available clinical and pharmacological data for Teneligliptin in the treatment of Diabetes mellitus.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
